158 related articles for article (PubMed ID: 11592859)
1. Pharmacological control of platelet function.
Clutton P; Folts JD; Freedman JE
Pharmacol Res; 2001 Oct; 44(4):255-64. PubMed ID: 11592859
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological approaches to studying platelet function: an overview.
Hourani SM
Methods Mol Biol; 2004; 273():73-86. PubMed ID: 15308794
[No Abstract] [Full Text] [Related]
3. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
4. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
7. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
8. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
10. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
11. [Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action].
Khaspekova SG; Sirotkina OV; Shimanova IuV; Mazurov AV
Biomed Khim; 2008; 54(3):361-71. PubMed ID: 18712091
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Konstantopoulos K; Mousa SA
Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of platelet activation and development of antiplatelet agents].
Cazenave JP; Gachet C; Lanza F
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
15. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Goto S; Tamura N; Ishida H; Ruggeri ZM
J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
[TBL] [Abstract][Full Text] [Related]
16. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
17. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Nurden AT
Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
[TBL] [Abstract][Full Text] [Related]
18. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
[TBL] [Abstract][Full Text] [Related]
20. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]